View Author
patient cannabi cannabis use load decrease study hepatitis effect psychosi group response hcv mono-infected patients fi rst phase genotype hepatitis c decrease hcv /hiv patients therapy mono-infected schizophrenia disorder slope interaction virus analysis treatment phase baseline sample fi rst-phase ribavirin winkel psychiatry lifetime outcome kinetic hepatitis c virus rst-phase akt 1 performance onset van winkel cognition interferon measure investigator responder cidi lifetime use hcv mono-infected alteration association control netherland cannabis-induced urinalysi difference hcv-rna hepatitis c mono-infected university rvr patients ficiency period eli lilly week 12 peginterferon-alfa health plasma virological response accuracy non-rvr assessment non-rvr patients reaction immunode ficiency virus data analysis second-phase slope hiv /hcv patients genotype 1 assay factor attention
2 Most Recent Publications
|
AKT1 Moderation of Cannabis-Induced Cognitive Alterations in Psychotic Disorder
(Article)
Winkel, R. van Beveren, N.J.M. van Krabbendam, L. Myin-Germeys, I. Simons, C.P.M. Kahn, R.S. Linszen, D. Os, J. van Wiersma, D. Bruggeman, R. Cahn, W. Haan, L. de |
2011-07-20
|
|
Plasma HCV-RNA decline in the first 48 h identifies hepatitis C virus mono-infected but not HCVHIV-coinfected patients with an undetectable HCV viral load at week 4 of peginterferon-alfa-2aribavirin therapy
(Article)
Arends, J.E. Stuart, J.C. Baak, L.C. Ende, M.E. van der Erpecum, K.J. van Simons, C.P.M. Boland , G.J. Baarle, D. van Hoepelman, I.M. |
2009-12-01
|
